Medtronic plc. (MDT) Stake Raised by WINTON GROUP Ltd
WINTON GROUP Ltd increased its holdings in Medtronic plc. (NYSE:MDT) by 340.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,164 shares of the medical technology company’s stock after purchasing an additional 59,625 shares during the period. WINTON GROUP Ltd’s holdings in Medtronic were worth $6,231,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Medtronic by 2.4% in the second quarter. Vanguard Group Inc. now owns 104,776,036 shares of the medical technology company’s stock valued at $9,298,872,000 after purchasing an additional 2,454,380 shares during the period. BlackRock Inc. grew its position in shares of Medtronic by 6.4% in the fourth quarter. BlackRock Inc. now owns 94,595,580 shares of the medical technology company’s stock valued at $7,638,592,000 after purchasing an additional 5,688,180 shares during the period. Artisan Partners Limited Partnership grew its position in shares of Medtronic by 1.1% in the third quarter. Artisan Partners Limited Partnership now owns 23,853,034 shares of the medical technology company’s stock valued at $1,855,050,000 after purchasing an additional 269,814 shares during the period. Lazard Asset Management LLC grew its position in shares of Medtronic by 43.8% in the second quarter. Lazard Asset Management LLC now owns 19,669,866 shares of the medical technology company’s stock valued at $1,745,699,000 after purchasing an additional 5,991,094 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Medtronic by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 14,191,675 shares of the medical technology company’s stock valued at $1,143,549,000 after purchasing an additional 351,256 shares during the period. 79.89% of the stock is owned by institutional investors and hedge funds.
Medtronic plc. (NYSE MDT) opened at $77.84 on Monday. The company has a market capitalization of $106,166.38, a PE ratio of 38.59, a price-to-earnings-growth ratio of 2.22 and a beta of 0.97. Medtronic plc. has a one year low of $76.51 and a one year high of $89.72. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.09 and a current ratio of 2.43.
In other Medtronic news, VP Richard Kuntz sold 78,526 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the transaction, the vice president now owns 149,761 shares in the company, valued at $12,910,895.81. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Hooman Hakami sold 26,158 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $85.00, for a total value of $2,223,430.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,684 shares of company stock worth $10,318,276. 0.31% of the stock is currently owned by insiders.
A number of equities research analysts have recently commented on the company. Stifel Nicolaus lifted their price objective on Medtronic from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Wednesday, November 22nd. Argus raised Medtronic from a “hold” rating to a “buy” rating and lifted their price objective for the company from $81.27 to $95.00 in a research report on Tuesday, December 12th. They noted that the move was a valuation call. Oppenheimer reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Medtronic in a research report on Wednesday, November 22nd. Needham & Company LLC reissued a “buy” rating and set a $94.00 price target on shares of Medtronic in a research report on Thursday, November 9th. Finally, Morgan Stanley boosted their price target on Medtronic from $91.00 to $95.00 and gave the company an “equal weight” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $91.50.
WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/03/05/medtronic-plc-mdt-stake-raised-by-winton-group-ltd.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.